Order of the General Court of 7 March 2017 — SymbioPharm v EMA

(Case T-295/16) (1)

((Action for annulment - Medicinal products for human use - Commencement of the procedure for referral to the EMA - Articles 31 to 34 of Directive 2001/83/EC - Medicinal product Symbioflor 2 and medicinal products with similar designations - Act not open to challenge - Preparatory act - Inadmissibility))

(2017/C 144/61)

Language of the case: German

Parties

Applicant: SymbioPharm GmbH (Herborn, Germany) (represented by: A. Sander, lawyer)

Defendant: European Medicines Agency (EMA) (represented by: T. Jabłoński, N. Rampal Olmedo, I. Ratescu, acting as Agents)

Re:

Application based on Article 263 TFEU asking for annulment of the letter from the EMA of 1 April 2016 to initiate a referral procedure referred to in Articles 32 to 34 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), concerning medicinal product Symbioflor 2 and similarly named medicinal products following a notification by the Federal Republic of Germany under Article 31 of that Directive.

Operative part of the order

(1)  OJ C 279, 1.8.2016.